No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
XORTX Therapeutics Delays Yearly Report Filing
XORTX Therapeutics Receives Response From FDA Regarding XORLO's NDA For Gout Treatment
XRTX Stock Has Given up Its Prior Gain. XORTX Therapeutics Shares Were Trading Higher After the Comapny Announced That the Patent "Xanthine Oxidase Inhibitor Formulations" Will Be Granted by the European Patent Office.
XORTX Therapeutics 14% Higher in U.S. Pre-market Trading After Gaining European Patent
XORTX Announces Receipt Of Patent For Xanthine Oxidase Inhibitor Formulations By European Patent Office
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
